GLP-1 medications linked to bone, muscle, and brain health concerns

The widespread use of GLP-1 medications for obesity and diabetes is raising significant medical concerns regarding physiological side effects. Research indicates that rapid weight loss can lead to reductions in bone mineral density and muscle mass, potentially increasing fracture risks and compromising mobility. Experts warn that extreme caloric deficits may also impact brain health by depriving the organ of necessary energy and nutrients.

In pediatric populations, use of these drugs among children aged 8 to 11 has increased significantly, though overall prescription rates remain low. Financial barriers also impact adherence; a study found a tipping point at $75 in monthly out-of-pocket costs, beyond which nonadherence rose to over 80%.

Regarding pregnancy, a meta-analysis published in The Lancet suggests that GLP-1 exposure in the first trimester is not associated with increased congenital malformations or preterm births. However, some data indicated a higher frequency of early pregnancy loss, though researchers noted this requires further investigation to distinguish between natural losses and medication-related effects. Medical professionals emphasize that these treatments should be used under clinical supervision, ideally combined with resistance exercise and adequate nutrition to mitigate musculoskeletal loss.